Cited by 133Cancer Immunotherapy and BiomarkersImmunotherapy and Immune ResponsesT-cell and B-cell Immunology

The DOI matches its Crossref record; 125 of the 126 references it cites were found in a registry or an index.

Immunotherapy comes of age: Immune aging & checkpoint inhibitors

Elias, Rawad, Karantanos, Theodoros, Sira, Elizabeth, Hartshorn, Kevan L.·2017·Journal of Geriatric Oncology

DOI 10.1016/j.jgo.2017.02.001

Open this paper in CoChat — free account

Abstract

Immune checkpoint inhibitors (ICIs) are based on the understanding that there are multilayered checks and balances which can be manipulated to unleash already existing, but paralyzed, immune responses to cancer. These agents are safer and more efficacious than classic cytotoxic drugs making them a very attractive therapeutic option, especially in older adults. Current available data do not suggest significant age-associated differences in the clinical profile of ICIs. It must be noted, however, that there is still relatively little information on the use of ICIs in adults over 75years of age and aging is associated with a decline in the immune system or "immunosenescence" which theoretically can reduce the efficacy of these immune based therapies. In this paper, we review the mechanism of action of ICIs, current clinical data on their use in older adults, and age-associated immune changes that might have a direct impact on their activity in this population. We chose to focus on mainly adaptive cellular immunity, and especially on components of the immune system that are implicated directly in the immune checkpoint process.

Integrity signals

Registry

Crossref · 10.1016/j.jgo.2017.02.001

Cites

125 of 125 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer
Reck, M., Rodríguez-Abreu, D., Robinson, A. G., Hui, R., Csőszi, T., Fülöp, A., Gottfried, M., Peled, N., Tafreshi, A., Cuffe, S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1606774 · Cited by 10,089
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., Skora, A. D., Luber, B. S., Azad, N. S., Laheru, D., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500596 · Cited by 9,377
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
Motzer, R. J., Escudier, B., McDermott, D. F., George, S., Hammers, H. J., Srinivas, S., Tykodi, S. S., Sosman, J. A., Procopio, G., Plimack, E. R., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1510665 · Cited by 5,807
Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer
Kantoff, P. W., Higano, C. S., Shore, N. D., Berger, E. R., Small, E. J., Penson, D. F., Redfern, C. H., Ferrari, A. C., Dreicer, R., Sims, R. B., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1001294 · Cited by 5,572
PD-1 and Its Ligands in Tolerance and Immunity
Keir, M. E., Butte, M. J., Freeman, G. J., & Sharpe, A. H. (2008) · Annual Review of Immunology · doi:10.1146/annurev.immunol.26.021607.090331 · Cited by 5,378
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
Herbst, R. S., Soria, J.-C., Kowanetz, M., Fine, G. D., Hamid, O., Gordon, M. S., Sosman, J. A., McDermott, D. F., Powderly, J. D., Gettinger, S. N., et al. (2014) · Nature · doi:10.1038/nature14011 · Cited by 5,231
Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival
Curiel, T. J., Coukos, G., Zou, L., Alvarez, X., Cheng, P., Mottram, P., Evdemon-Hogan, M., Conejo-Garcia, J. R., Zhang, L., Burow, M., et al. (2004) · Nature Medicine · doi:10.1038/nm1093 · Cited by 5,151
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
Ferris, R. L., Blumenschein, G., Fayette, J., Guigay, J., Colevas, A. D., Licitra, L., Harrington, K., Kasper, S., Vokes, E. E., Even, C., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1602252 · Cited by 5,101
Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion
Dong, H., Strome, S. E., Salomao, D. R., Tamura, H., Hirano, F., Flies, D. B., Roche, P. C., Lu, J., Zhu, G., Tamada, K., et al. (2002) · Nature Medicine · doi:10.1038/nm730 · Cited by 5,025
The immune contexture in human tumours: impact on clinical outcome
Fridman, W. H., Pagès, F., Sautès-Fridman, C., & Galon, J. (2012) · Nature reviews. Cancer · doi:10.1038/nrc3245 · Cited by 4,981
Restoring function in exhausted CD8 T cells during chronic viral infection
Barber, D. L., Wherry, E. J., Masopust, D., Zhu, B., Allison, J. P., Sharpe, A. H., Freeman, G. J., & Ahmed, R. (2005) · Nature · doi:10.1038/nature04444 · Cited by 4,057
Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial
Rosenberg, J. E., Hoffman-Censits, J., Powles, T., van der Heijden, M. S., Balar, A. V., Necchi, A., Dawson, N., O'Donnell, P. H., Balmanoukian, A., Loriot, Y., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)00561-4 · Cited by 3,669
PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
Ansell, S. M., Lesokhin, A. M., Borrello, I., Halwani, A. S., Scott, E. C., Gutierrez, M. E., Schuster, S. J., Millenson, M. M., Cattry, D., Freeman, G. J., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1411087 · Cited by 3,621
Induced expression of PD‐1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death.
Ishida, Y., Agata, Y., Shibahara, K., & Honjo, T. (1992) · The EMBO Journal · doi:10.1002/j.1460-2075.1992.tb05481.x · Cited by 3,259
Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial
Fehrenbacher, L., Spira, A., Ballinger, M., Kowanetz, M., Vansteenkiste, J., Mazieres, J., Park, K., Smith, D., Artal-Cortes, A., Lewanski, C., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)00587-0 · Cited by 2,756
Colocalization of Inflammatory Response with B7-H1 Expression in Human Melanocytic Lesions Supports an Adaptive Resistance Mechanism of Immune Escape
Taube, J. M., Anders, R. A., Young, G. D., Xu, H., Sharma, R., McMiller, T. L., Chen, S., Klein, A. P., Pardoll, D. M., Topalian, S. L., et al. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3003689 · Cited by 2,157
Irradiation and anti–PD-L1 treatment synergistically promote antitumor immunity in mice
Deng, L., Liang, H. L., Burnette, B., Beckett, M., Darga, T. E., Weichselbaum, R. R., & Fu, Y. (2014) · Journal of Clinical Investigation · doi:10.1172/jci67313 · Cited by 2,119
PD-L1 regulates the development, maintenance, and function of induced regulatory T cells
Francisco, L. M., Salinas, V. H., Brown, K. E., Vanguri, V. K., Freeman, G. J., Kuchroo, V. K., & Sharpe, A. H. (2009) · The Journal of Experimental Medicine · doi:10.1084/jem.20090847 · Cited by 2,072
Up-Regulation of PD-L1, IDO, and T regs in the Melanoma Tumor Microenvironment Is Driven by CD8 + T Cells
Spranger, S., Spaapen, R. M., Zha, Y., Williams, J., Meng, Y., Ha, T. T., & Gajewski, T. F. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3006504 · Cited by 1,677
Inhibitory B7-family molecules in the tumour microenvironment
Zou, W., & Chen, L. (2008) · Nature Reviews Immunology · doi:10.1038/nri2326 · Cited by 1,608
Immunological effects of conventional chemotherapy and targeted anticancer agents
Galluzzi, L., Buqué, A., Kepp, O., Zitvogel, L., & Kroemer, G. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.10.012 · Cited by 1,530
The vigorous immune microenvironment of microsatellite instable colon cancer is balanced by multiple counter-inhibitory checkpoints
Llosa, N. J., Cruise, M., Tam, A., Wicks, E. C., Hechenbleikner, E. M., Taube, J. M., Blosser, R. L., Fan, H., Wang, H., Luber, B. S., et al. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-0863 · Cited by 1,487
Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma
Simpson, T. R., Li, F., Montalvo-Ortiz, W., Sepulveda, M. A., Bergerhoff, K., Arce, F., Roddie, C., Henry, J. Y., Yagita, H., Wolchok, J. D., et al. (2013) · Journal of Experimental Medicine · doi:10.1084/jem.20130579 · Cited by 1,472
Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma
Parsa, A. T., Waldron, J. S., Panner, A., Crane, C. A., Parney, I. F., Barry, J. J., Cachola, K. E., Murray, J. C., Tihan, T., Jensen, M. C., et al. (2006) · Nature Medicine · doi:10.1038/nm1517 · Cited by 1,341
Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity
Curiel, T. J., Wei, S., Dong, H., Alvarez, X., Cheng, P., Mottram, P., Krzysiek, R., Knutson, K. L., Daniel, B., Zimmermann, M. C., et al. (2003) · Nature Medicine · doi:10.1038/nm863 · Cited by 1,314
Quantification of Regulatory T Cells Enables the Identification of High-Risk Breast Cancer Patients and Those at Risk of Late Relapse
Bates, G. J., Fox, S. B., Cheng, H., Leek, R., García, J. F. S., Harris, A. L., & Banham, A. H. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.05.9584 · Cited by 1,244
Hyperprogressive Disease Is a New Pattern of Progression in Cancer Patients Treated by Anti-PD-1/PD-L1
Champiat, S., Dercle, L., Ammari, S., Massard, C., Hollebecque, A., Postel-Vinay, S. C., Chaput, N., Eggermont, A. M. M., Marabelle, A., Soria, J., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-1741 · Cited by 1,204
Safety and Antitumor Activity of Anti–PD-1 Antibody, Nivolumab, in Patients With Platinum-Resistant Ovarian Cancer
Hamanishi, J., Mandai, M., Ikeda, T., Minami, M., Kawaguchi, A., Murayama, T., Kanai, M., Mori, Y., Matsumoto, S., Chikuma, S., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.62.3397 · Cited by 1,193
Foxp3-dependent programme of regulatory T-cell differentiation
Gavin, M. A., Rasmussen, J. P., Fontenot, J. D., Vasta, V., Manganiello, V. C., Beavo, J. A., & Rudensky, A. Y. (2007) · Nature · doi:10.1038/nature05543 · Cited by 1,127
Molecular Diagnosis of Primary Mediastinal B Cell Lymphoma Identifies a Clinically Favorable Subgroup of Diffuse Large B Cell Lymphoma Related to Hodgkin Lymphoma
Rosenwald, A., Wright, G. W., Leroy, K., Yu, X., Gaulard, P., Gascoyne, R. D., Chan, W. C., Zhao, T., Haïoun, C., Greiner, T. C., et al. (2003) · The Journal of Experimental Medicine · doi:10.1084/jem.20031074 · Cited by 1,118
Deficiencies in DNA damage repair limit the function of haematopoietic stem cells with age
Rossi, D. J., Bryder, D., Seita, J., Nussenzweig, A., Hoeijmakers, J., & Weissman, I. L. (2007) · Nature · doi:10.1038/nature05862 · Cited by 1,115
Expression of CD57 defines replicative senescence and antigen-induced apoptotic death of CD8+ T cells
Brenchley, J. M., Karandikar, N. J., Betts, M. R., Ambrozak, D. R., Hill, B. J., Crotty, L. E., Casazza, J. P., Kuruppu, J., Migueles, S. A., Connors, M., et al. (2003) · Blood · doi:10.1182/blood-2002-07-2103 · Cited by 1,073
Regulatory T cells in tumor immunity
Nishikawa, H., & Sakaguchi, S. (2010) · International Journal of Cancer · doi:10.1002/ijc.25429 · Cited by 944
Genome-wide analysis of Foxp3 target genes in developing and mature regulatory T cells
Zheng, Y., Josefowicz, S. Z., Kas, A., Chu, T.-T., Gavin, M. A., & Rudensky, A. Y. (2007) · Nature · doi:10.1038/nature05563 · Cited by 835
The emerging role of CTLA4 as a cell-extrinsic regulator of T cell responses
Walker, L. S. K., & Sansom, D. M. (2011) · Nature reviews. Immunology · doi:10.1038/nri3108 · Cited by 817
The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti–PD-1 antibody
Benson, D. M., Bakan, C. E., Mishra, A., Hofmeister, C. C., Efebera, Y., Becknell, B., Baiocchi, R. A., Zhang, J., Yu, J., Smith, M. K., et al. (2010) · Blood · doi:10.1182/blood-2010-02-271874 · Cited by 807
The Influence of Age on T Cell Generation and TCR Diversity
Naylor, K., Li, G., Vallejo, A. N., Lee, W.-W., Koetz, K., Bryl, E., Witkowski, J., Fulbright, J., Weyand, C. M., & Goronzy, J. J. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.174.11.7446 · Cited by 802
PD-L1/B7H-1 Inhibits the Effector Phase of Tumor Rejection by T Cell Receptor (TCR) Transgenic CD8+ T Cells
Blank, C., Brown, I., Peterson, A. C., Spiotto, M., Iwai, Y., Honjo, T., & Gajewski, T. F. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-3259 · Cited by 772
Enhancing SIV-specific immunity in vivo by PD-1 blockade
Velu, V., Titanji, K., Zhu, B., Husain, S., Pladevega, A., Lai, L., Vanderford, T. H., Chennareddi, L. S., Silvestri, G., Freeman, G. J., et al. (2008) · Nature · doi:10.1038/nature07662 · Cited by 765
Oncogenic kinase NPM/ALK induces through STAT3 expression of immunosuppressive protein CD274 (PD-L1, B7-H1)
Marzec, M., Zhang, Q., Goradia, A., Raghunath, P. N., Liu, X., Paessler, M. E., Wang, H. Y., Wysocka, M., Cheng, M. M., Ruggeri, B., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0810958105 · Cited by 731
CD28− T cells: their role in the age-associated decline of immune function
Weng, N., Akbar, A. N., & Goronzy, J. J. (2009) · Trends in Immunology · doi:10.1016/j.it.2009.03.013 · Cited by 630
The ageing haematopoietic stem cell compartment
Geiger, H., de Haan, G., & Florian, M. C. (2013) · Nature Reviews Immunology · doi:10.1038/nri3433 · Cited by 604
Innate Immune Recognition of Cancer
Woo, S., Corrales, L. P., & Gajewski, T. F. (2015) · Annual Review of Immunology · doi:10.1146/annurev-immunol-032414-112043 · Cited by 587
Age-associated decrease in TLR function in primary human dendritic cells predicts influenza vaccine response
Panda, A., Qian, F., Mohanty, S., van Duin, D., Newman, F. K., Zhang, L., Chen, S., Towle, V., Belshe, R. B., Fikrig, E., et al. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.0901022 · Cited by 548
Erratum: Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion
Dong, H., Strome, S. E., Salomão, D. R., Tamura, H., Hirano, F., Flies, D. B., Roche, P. C., Lu, J., Zhu, G., Tamada, K., et al. (2002) · Nature Medicine · doi:10.1038/nm0902-1039c · Cited by 545
CD4 + CD25 + regulatory T cells in patients with gastrointestinal malignancies
Sasada, T., Kimura, M., Yoshida, Y., Kanai, M., & Takabayashi, A. (2003) · Cancer · doi:10.1002/cncr.11618 · Cited by 485
T cell subset-specific susceptibility to aging
Czesnikiewicz-Guzik, M., Lee, W.-W., Cui, D., Hiruma, Y., Lamar, D. L., Yang, Z.-Z., Ouslander, J. G., Weyand, C. M., & Goronzy, J. J. (2008) · Clinical Immunology · doi:10.1016/j.clim.2007.12.002 · Cited by 478
Lymphostromal interactions in thymic development and function
Anderson, G., & Jenkinson, E. J. (2001) · Nature reviews. Immunology · doi:10.1038/35095500 · Cited by 466
Tumor infiltrating Foxp3+ regulatory T‐cells are associated with recurrence in pathologic stage I NSCLC patients
Petersen, R. P., Campa, M. J., Sperlazza, J. R., Conlon, D. H., Joshi, M.-B., Harpole, D. H., & Patz, E. F. (2006) · Cancer · doi:10.1002/cncr.22282 · Cited by 446
Only pathologic complete response to neoadjuvant chemotherapy improves significantly the long term survival of patients with resectable esophageal squamous cell carcinoma
Ancona, E., Ruol, A., Santi, S., Merigliano, S., Chiarion‐Sileni, V., Koussis, H., Zaninotto, G., Bonavina, L., & Peracchia, A. (2001) · Cancer · doi:10.1002/1097-0142(20010601)91:11 · Cited by 434
Lymphoproliferation in CTLA-4–Deficient Mice Is Mediated by Costimulation-Dependent Activation of CD4 + T Cells
Chambers, C. A., Sullivan, T. J., & Allison, J. P. (1997) · Immunity · doi:10.1016/s1074-7613(00)80406-9 · Cited by 406
The number of human peripheral blood CD4+ CD25high regulatory T cells increases with age
Gregg, R., Smith, C. M., Clark, F. J., Dunnion, D., Khan, N., Chakraverty, R. K., Nayak, L., & Moss, P. A. H. (2005) · Clinical & Experimental Immunology · doi:10.1111/j.1365-2249.2005.02798.x · Cited by 383
IL-18 Induces PD-1–Dependent Immunosuppression in Cancer
Terme, M., Ullrich, E., Aymeric, L., Meinhardt, K., Desbois, M., Delahaye, N., Viaud, S., Ryffel, B., Yagita, H., Kaplanski, G., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-0993 · Cited by 376
Naive T Cell Maintenance and Function in Human Aging
Goronzy, J. J., Fang, F., Cavanagh, M., Qi, Q., & Weyand, C. M. (2015) · The Journal of Immunology · doi:10.4049/jimmunol.1500046 · Cited by 362
Multiparameter flow cytometric analysis of CD4 and CD8 T cell subsets in young and old people
Koch, S. D., Larbi, A., Derhovanessian, E., Özcelik, D., Naumova, E. J., & Pawelec, G. (2008) · Immunity & Ageing · doi:10.1186/1742-4933-5-6 · Cited by 360
Aging and cytomegalovirus infection differentially and jointly affect distinct circulating T cell subsets in humans
Wertheimer, A. M., Bennett, M. S., Park, B., Uhrlaub, J. L., Martinez, C., Pulko, V., Currier, N. L., Nikolich-Žugich, D., Kaye, J., & Nikolich-Žugich, J. (2014) · The Journal of Immunology · doi:10.4049/jimmunol.1301721 · Cited by 352
The aging innate immune system
Gómez, C. R., Boehmer, E. D., & Kovacs, E. J. (2005) · Current Opinion in Immunology · doi:10.1016/j.coi.2005.07.013 · Cited by 315
Comparison of efficacy of immune checkpoint inhibitors (ICIs) between younger and older patients: A systematic review and meta-analysis
Nishijima, T. F., Muss, H. B., Shachar, S. S., & Moschos, S. J. (2016) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2016.02.006 · Cited by 293
Aging is associated with a numerical and functional decline in plasmacytoid dendritic cells, whereas myeloid dendritic cells are relatively unaltered in human peripheral blood
Jing, Y., Shaheen, E., Drake, R. R., Chen, N., Gravenstein, S., & Deng, Y. (2009) · Human Immunology · doi:10.1016/j.humimm.2009.07.005 · Cited by 284
Aging and T-cell diversity☆
Goronzy, J. J., Lee, W., & Weyand, C. M. (2007) · Experimental Gerontology · doi:10.1016/j.exger.2006.11.016 · Cited by 269
CTLA4 blockade expands FoxP3+ regulatory and activated effector CD4+ T cells in a dose-dependent fashion
Kavanagh, B., O'Brien, S., Lee, D., Hou, Y., Weinberg, V., Rini, B., Allison, J. P., Small, E. J., & Fong, L. (2008) · Blood · doi:10.1182/blood-2007-11-125435 · Cited by 256
Ontogeny and Polarization of Macrophages in Inflammation: Blood Monocytes Versus Tissue Macrophages
Dey, A., Allen, J., & Hankey-Giblin, P. A. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00683 · Cited by 254
Senescence regulates macrophage activation and angiogenic fate at sites of tissue injury in mice
Kelly, J., Khan, A. A., Yin, J., Ferguson, T. A., & Apte, R. S. (2007) · Journal of Clinical Investigation · doi:10.1172/jci32430 · Cited by 249
Blood CD33(+)HLA-DR(−) myeloid-derived suppressor cells are increased with age and a history of cancer
Verschoor, C. P., Johnstone, J., Millar, J., Dorrington, M. G., Habibagahi, M., Lelic, A., Loeb, M., Bramson, J. L., & Bowdish, D. M. E. (2013) · Journal of Leukocyte Biology · doi:10.1189/jlb.0912461 · Cited by 235
Cell intrinsic mechanisms of T‐cell inhibition and application to cancer therapy
Peggs, K. S., Quezada, S. A., & Allison, J. P. (2008) · Immunological Reviews · doi:10.1111/j.1600-065x.2008.00649.x · Cited by 232
Myeloid-Derived Suppressor Cells in Human Cancer
Nagaraj, S., & Gabrilovich, D. I. (2010) · The Cancer Journal · doi:10.1097/ppo.0b013e3181eb3358 · Cited by 222
Advanced Age Impairs Macrophage Polarization
Mahbub, S., Deburghgraeve, C. R., & Kovacs, E. J. (2012) · Journal of Interferon & Cytokine Research · doi:10.1089/jir.2011.0058 · Cited by 222
The molecular pathogenesis of primary mediastinal large B-cell lymphoma
Steidl, C., & Gascoyne, R. D. (2011) · Blood · doi:10.1182/blood-2011-05-326538 · Cited by 212
Thymus Size and Age-related Thymic Involution: Early Programming, Sexual Dimorphism, Progenitors and Stroma.
Gui, J., Mustachio, L. M., Su, D., & Craig, R. W. (2012) · Europe PMC (PubMed Central) · Cited by 211
Reciprocal Relationship between Myeloid-Derived Suppressor Cells and T Cells
Nagaraj, S., Youn, J., & Gabrilovich, D. I. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1300654 · Cited by 186
Clonality and longevity of CD4+CD28null T cells are associated with defects in apoptotic pathways
Vallejo, A. N., Schirmer, M., Weyand, C. M., & Goronzy, J. J. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.165.11.6301 · Cited by 169
Age-associated impaired plasmacytoid dendritic cell functions lead to decreased CD4 and CD8 T cell immunity
Sridharan, A., Esposo, M., Kaushal, K., Tay, J., Osann, K., Agrawal, S., Gupta, S., & Agrawal, A. (2011) · AGE · doi:10.1007/s11357-010-9191-3 · Cited by 165
Homeostasis and function of regulatory T cells in aging
Raynor, J. L., Lages, C. S., Shehata, H. M., Hildeman, D. A., & Chougnet, C. A. (2012) · Current Opinion in Immunology · doi:10.1016/j.coi.2012.04.005 · Cited by 164
Nonantigen specific CD8+ T suppressor lymphocytes originate from CD8+CD28− T cells and inhibit both T-Cell proliferation and CTL function
Filaci, G., Fravega, M., Negrini, S., Procopio, F., Fenoglio, D., Rizzi, M., Brenci, S., Contini, P., Olive, D., Ghio, M., et al. (2004) · Human Immunology · doi:10.1016/j.humimm.2003.12.001 · Cited by 163
Impaired Interferon Signaling in Dendritic Cells From Older Donors Infected In Vitro With West Nile Virus
Qian, F., Wang, X., Zhang, L., Lin, A., Zhao, H., Fikrig, E., & Montgomery, R. R. (2011) · The Journal of Infectious Diseases · doi:10.1093/infdis/jir048 · Cited by 157
CD4+CD25+ T regulatory cells inhibit cytotoxic activity of CTL and NK cells in humans—impact of immunosenescence
Trzonkowski, P., Szmit, E., Myśliwska, J. M., & Myśliwski, A. (2006) · Clinical Immunology · doi:10.1016/j.clim.2006.02.002 · Cited by 152
Impaired Dendritic Cell Function in Aging Leads to Defective Antitumor Immunity
Grolleau‐Julius, A., Harning, E. K., Close, L. A., & Yung, R. L. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-5769 · Cited by 151
Blockade of PD‐1 or p38 MAP kinase signaling enhances senescent human CD8+ T‐cell proliferation by distinct pathways
Henson, S. M., Macaulay, R., Riddell, N. E., Nunn, C. J., & Akbar, A. N. (2015) · European Journal of Immunology · doi:10.1002/eji.201445312 · Cited by 146
Partial restoration of T‐cell function in aged mice by in vitro blockade of the PD‐1/ PD‐L1 pathway
Lages, C. S., Lewkowich, I. P., Sproles, A. A., Wills-Karp, M. A., & Chougnet, C. A. (2010) · Aging Cell · doi:10.1111/j.1474-9726.2010.00611.x · Cited by 141
Aging disturbs the balance between effector and regulatory CD4+ T cells
van der Geest, K. S. M., Abdulahad, W. H., Tete, S. M., Lorencetti, P. G., Horst, G., Bos, N. A., Kroesen, B., Brouwer, E., & Boots, A. M. H. (2014) · Experimental Gerontology · doi:10.1016/j.exger.2014.11.005 · Cited by 131
The role of CD4 T cell help for CD8 CTL activation
Zhang, S., Zhang, H., & Zhao, J. (2009) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2009.04.134 · Cited by 127
Age-associated alterations in the recruitment of signal-transduction proteins to lipid rafts in human T lymphocytes
Larbi, A., Douziech, N., Dupuis, G., Khalil, A., Pelletier, H., Guérard, K., & Fülöp, T. (2003) · Journal of Leukocyte Biology · doi:10.1189/jlb.0703319 · Cited by 126
Persistence of Tumor Infiltrating Lymphocytes in Adoptive Immunotherapy Correlates With Telomere Length
Shen, X., Zhou, J., Hathcock, K. S., Robbins, P. F., Powell, D. J., Rosenberg, S. A., & Hodes, R. J. (2006) · Journal of Immunotherapy · doi:10.1097/01.cji.0000211321.07654.b8 · Cited by 122
Dendritic cells in human aging
AGRAWAL, A., Agrawal, S., & Gupta, S. (2006) · Experimental Gerontology · doi:10.1016/j.exger.2006.11.007 · Cited by 122
Naïve T Cells in the Elderly
Pfister, G., Weiskopf, D., Lazuardi, L., Kovaiou, R. D., Cioca, D., Keller, M., LORBEG, B., Parson, W., & Grubeck‐Loebenstein, B. (2006) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1354.018 · Cited by 118
The characterization of varicella zoster virus-specific T cells in skin and blood during aging
Vukmanovic-Stejic, M., Sandhu, D., Seidel, J. A., Patel, N., Sobande, T. O., Agius, E., Jackson, S. E., Fuentes-Duculan, J., Suárez-Fariñas, M., Mabbott, N. A., et al. (2015) · Journal of Investigative Dermatology · doi:10.1038/jid.2015.63 · Cited by 117
New monoclonal antibodies against B-cell antigens: Possible new strategies for diagnosis of primary cutaneous B-cell lymphomas
Fanoni, D., Tavecchio, S., Recalcati, S., Balice, Y., Venegoni, L., Fiorani, R., CROSTI, C., & Berti, E. (2010) · Immunology Letters · doi:10.1016/j.imlet.2010.09.022 · Cited by 115
Age-related deregulation of naive T cell homeostasis in elderly humans
Ferrando‐Martínez, S., Ruíz-Mateos, E., Hernández, A., Gutiérrez, E., Rodríguez-Méndez, M. M., Ordóñez, A., & Leal, M. (2010) · AGE · doi:10.1007/s11357-010-9170-8 · Cited by 113
B7-H1 on myeloid-derived suppressor cells in immune suppression by a mouse model of ovarian cancer
Liu, Y., Zeng, B., Zhang, Z., Zhang, Y. C., & Yang, R. (2008) · Clinical Immunology · doi:10.1016/j.clim.2008.07.030 · Cited by 102
Impact of HIV on CD8+ T Cell CD57 Expression Is Distinct from That of CMV and Aging
Lee, S. A., Sinclair, E., Hatano, H., Hsue, P. Y., Epling, L., Hecht, F. M., Bangsberg, D. R., Martin, J. N., McCune, J. M., Deeks, S. G., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0089444 · Cited by 102
Induction of Cytotoxic T Lymphocyte Antigen 4 (Ctla-4) Restricts Clonal Expansion of Helper T Cells
Doyle, A. M., Mullen, A. C., Villarino, A. V., Hutchins, A. S., High, F. A., Lee, H. W., Thompson, C. B., & Reiner, S. L. (2001) · The Journal of Experimental Medicine · doi:10.1084/jem.194.7.893 · Cited by 102
Impaired antigen-induced CD8+ T cell clonal expansion in aging is due to defects in antigen presenting cell function
Plowden, J., Renshaw-Hoelscher, M., Gangappa, S., Engleman, C., Katz, J. M., & Sambhara, S. (2004) · Cellular Immunology · doi:10.1016/j.cellimm.2004.07.001 · Cited by 98
Effects of aging on early B‐ and T‐cell development
Min, H., Montecino‐Rodriguez, E., & Dorshkind, K. (2005) · Immunological Reviews · doi:10.1111/j.0105-2896.2005.00263.x · Cited by 96
Enumeration of human peripheral blood dendritic cells throughout the life
Orsini, G., Legitimo, A., Failli, A., Massei, F., Biver, P., & Consolini, R. (2012) · International Immunology · doi:10.1093/intimm/dxs006 · Cited by 91
Influenza-Induced Production of Interferon-Alpha is Defective in Geriatric Individuals
Canaday, D. H., Amponsah, N. A., Jones, L., Tisch, D. J., Hornick, T. R., & Ramachandra, L. (2010) · Journal of Clinical Immunology · doi:10.1007/s10875-010-9374-9 · Cited by 89
The frequency of regulatory CD3+CD8+CD28−CD25+ T lymphocytes in human peripheral blood increases with age
Simone, R., Zicca, A., & Saverino, D. (2008) · Journal of Leukocyte Biology · doi:10.1189/jlb.0907627 · Cited by 88
Ageing, autoimmunity and arthritis: Perturbations of TCR signal transduction pathways with ageing – a biochemical paradigm for the ageing immune system
Fülöp, T., Larbi, A., Dupuis, G., & Pawelec, G. (2003) · Arthritis Research & Therapy · doi:10.1186/ar1019 · Cited by 81
Reduced numbers of plasmacytoid dendritic cells in aged blood donors
Pérez-Cabezas, B., Naranjo-Gómez, M., Fernández, M. A., Grífols, J. R., Pujol-Borrell, R., & Borràs, F. E. (2007) · Experimental Gerontology · doi:10.1016/j.exger.2007.05.010 · Cited by 80
Impaired secretion of interferons by dendritic cells from aged subjects to influenza
Prakash, S., Agrawal, S., Cao, J., Gupta, S., & Agrawal, A. (2012) · AGE · doi:10.1007/s11357-012-9477-8 · Cited by 79
Costimulatory mechanisms in the elderly
Effros, R. B. (2000) · Vaccine · doi:10.1016/s0264-410x(99)00503-4 · Cited by 79
Can exercise-related improvements in immunity influence cancer prevention and prognosis in the elderly?
Bigley, A. B., Spielmann, G., LaVoy, E. C. P., & Simpson, R. J. (2013) · Maturitas · doi:10.1016/j.maturitas.2013.06.010 · Cited by 78
Age‐related alterations of gene expression patterns in human CD8+ T cells
Cao, J., Gollapudi, S., Sharman, E. H., Jia, Z., & Gupta, S. (2010) · Aging Cell · doi:10.1111/j.1474-9726.2009.00534.x · Cited by 71
The aging bone marrow and its impact on immune responses in old age
Pritz, T., Weinberger, B., & Grubeck‐Loebenstein, B. (2014) · Immunology Letters · doi:10.1016/j.imlet.2014.06.016 · Cited by 71
Increased tumor-infiltrating CD8+Foxp3+ T lymphocytes are associated with tumor progression in human gastric cancer
Peng, L., Zhuang, Y., Shi, Y., Zhao, Y., Wang, T., Chen, N., Cheng, P., Liu, T., Liu, X.-F., Zhang, J., et al. (2012) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-012-1277-6 · Cited by 60
Adenosine Deaminase Modulation of Telomerase Activity and Replicative Senescence in Human CD8 T Lymphocytes
Parish, S. T., Kim, S., Sekhon, R. K., Wu, J. E., Kawakatsu, Y., & Effros, R. B. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.0903647 · Cited by 59
Immune checkpoint inhibitors in older adults
Elias, R., Morales, J., Rehman, Y., & Khurshid, H. (2016) · Current Oncology Reports · doi:10.1007/s11912-016-0534-9 · Cited by 59
CD95-mediated apoptosis in naïve, central and effector memory subsets of CD4+ and CD8+ T cells in aged humans.
Gupta, S., & Gollapudi, S. (2008) · Experimental Gerontology · doi:10.1016/j.exger.2007.12.006 · Cited by 57
As we age: Does slippage of quality control in the immune system lead to collateral damage?
Müller, L., & Pawelec, G. (2015) · Ageing Research Reviews · doi:10.1016/j.arr.2015.01.005 · Cited by 52
Plasmacytoid dendritic cells and their Toll-like receptor 9 expression selectively decrease with age
Garbe, K., Bratke, K., Wagner, S., Virchow, J. C., Jr., & Lommatzsch, M. (2012) · Human Immunology · doi:10.1016/j.humimm.2012.02.007 · Cited by 49
Naïve and memory CD8 T cell pool homeostasis in advanced aging: impact of age and of antigen-specific responses to cytomegalovirus
Vescovini, R., Fagnoni, F. F., Telera, A. R., Bucci, L., Pedrazzoni, M., Magalini, F., Stella, A., Pasin, F., Medici, M. C., Calderaro, A., et al. (2014) · AGE · doi:10.1007/s11357-013-9594-z · Cited by 48
Immunomodulatory role of high-density lipoproteins: impact on immunosenescence
Larbi, A., Fortin, C. F., Dupuis, G., Berrougui, H., Khalil, A., & Fülöp, T. (2014) · AGE · doi:10.1007/s11357-014-9712-6 · Cited by 47
Efficacy and safety of checkpoint blockade for treatment of advanced melanoma (mel) in patients (pts) age 80 and older (80+).
Friedman, C. F., Horvat, T. Z., Minehart, J. C., Panageas, K. S., Callahan, M. K., Chapman, P. B., Momtaz, P., Postow, M. A., Shoushtari, A. N., Wolchok, J. D., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.34.15_suppl.10009 · Cited by 47
Aging-associated subpopulations of human CD8+ T-lymphocytes identified by their CD28 and CD57 phenotypes
Onyema, O. O., Njemini, R., Forti, L. N., Bautmans, I., Aerts, J. L., Waele, M. D., & Mets, T. F. (2015) · Archives of Gerontology and Geriatrics · doi:10.1016/j.archger.2015.08.007 · Cited by 45
Dysfunction of dendritic cells in aged C57BL/6 mice leads to failure of natural killer cell activation and of tumor eradication
Guo, Z., Tilburgs, T., Wong, B., & Strominger, J. L. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1414780111 · Cited by 40
Tumor-Infiltrating Dendritic Cells May Be Used as Clinicopathologic Prognostic Factors in Endometrial Carcinoma
Lijun, Z., Xin, Z., Danhua, S., Li, X., Wang, J., Huilan, W., & Lihui, W. (2012) · International Journal of Gynecological Cancer · doi:10.1097/igc.0b013e31825401c6 · Cited by 38
Decline of T cell-related immune functions in cancer patients and an attempt to restore them through infusion of activated autologous T cells
Hirokawa, K., Utsuyama, M., Ishikawa, T., Kikuchi, Y., Kitagawa, M., Fujii, Y., Hideo, N., Uetake, H., & Sugihara, K. (2008) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2008.05.001 · Cited by 34
A population biological approach to understanding the maintenance and loss of the T‐cell repertoire during aging
Johnson, P. L. F., Goronzy, J. J., & Antia, R. (2014) · Immunology · doi:10.1111/imm.12244 · Cited by 34
Is there a clinical benefit of anti-PD-1 in patients older than 75 years with previously treated solid tumour?
Landre, T., Taleb, C., Nicolas, P., & Guetz, G. D. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.34.15_suppl.3070 · Cited by 32
Are macrophages, myeloid derived suppressor cells and neutrophils mediators of local suppression in healthy and cancerous tissues in aging hosts?
Jackaman, C., & Nelson, D. J. (2013) · Experimental Gerontology · doi:10.1016/j.exger.2013.11.009 · Cited by 31
Gene expression and generation of CD28−CD8 T cells mediated by interleukin 15
Godlove, J. M., CHIU, W., & Weng, N. (2007) · Experimental Gerontology · doi:10.1016/j.exger.2006.11.015 · Cited by 29
Immunosenescence in the nursing home elderly
Johnstone, J., Millar, J., Lelic, A., Verschoor, C. P., Walter, S. D., Devereaux, P. J., Bramson, J. L., & Loeb, M. B. (2014) · BMC Geriatrics · doi:10.1186/1471-2318-14-50 · Cited by 27
Myeloid-derived suppressor cells promote age-related increase of lung cancer growth via B7-H1
Chen, S., Liu, H., Su, N., Zhang, G., & Wang, L. (2014) · Experimental Gerontology · doi:10.1016/j.exger.2014.12.001 · Cited by 23
Differences in TCR-Vβ Repertoire and Effector Phenotype between Tumor Infiltrating Lymphocytes and Peripheral Blood Lymphocytes Increase with Age
Shao, H., Ou, Y., Wang, T., Shen, H., Wu, F., Zhang, W., Tao, C., Yin, Y., Bo, H., Wang, H., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0102327 · Cited by 18
Safety and preliminary efficacy of nivolumab (nivo) in patients (pts) with advanced hepatocellular carcinoma (aHCC): Interim analysis of the phase 1/2 CheckMate-040 study
Melero, I., Sangro, B., Yau, T. C. C., Hsu, C., Kudo, M., Crocenzi, T. S., Kim, T.-Y., Choo, S. P., Trojan, J., Meyer, T., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw371.07 · Cited by 5
219O Safety and preliminary efficacy of nivolumab in patients with advanced hepatocellular carcinoma: interim analysis of the phase 1/2 CheckMate-040 study
Melero, I., Sangro, B., Yau, T. O., Hsu, C.-H., Kudo, M., Crocenzi, T. S., Kim, T.-Y., Choo, S. P., Trojan, J., Meyer, T., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw582 · Cited by 4

Research works printed but not linked: 1

Singh, 2016, FDA subset analysis of the safety of nivolumab in elderly patients with advanced cancers. | 2016 ASCO Annual Meeting | Abstracts | Meeting Library, J Clin Oncol, 34

Sorted by citations

Immunosenescence and Inflamm-Aging As Two Sides of the Same Coin: Friends or Foes?
Fulop, T., Larbi, A., Dupuis, G., Le Page, A., Frost, E. H., Cohen, A. A., Witkowski, J. M., & Franceschi, C. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01960 · Cited by 1,364
How the ageing microenvironment influences tumour progression
Fane, M., & Weeraratna, A. T. (2020) · Nature Reviews Cancer · doi:10.1038/s41568-019-0222-9 · Cited by 849
Immunosenescence and Its Hallmarks: How to Oppose Aging Strategically? A Review of Potential Options for Therapeutic Intervention
Aiello, A., Farzaneh, F., Candore, G., Caruso, C., Davinelli, S., Gambino, C. M., Ligotti, M. E., Zareian, N., & Accardi, G. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02247 · Cited by 693
The integration of inflammaging in age-related diseases
Fülöp, T., Witkowski, J. M., Olivieri, F., & Larbi, A. (2018) · Seminars in Immunology · doi:10.1016/j.smim.2018.09.003 · Cited by 368
Safety and efficacy of pembrolizumab monotherapy in elderly patients with PD-L1–positive advanced non–small-cell lung cancer: Pooled analysis from the KEYNOTE-010, KEYNOTE-024, and KEYNOTE-042 studies
Nosaki, K., Saka, H., Hosomi, Y., Baas, P., de Castro, G., Reck, M., Wu, Y.-L. L. C., Brahmer, J. R., Felip, E., Sawada, T., et al. (2019) · Lung Cancer · doi:10.1016/j.lungcan.2019.07.004 · Cited by 292

See all 133

Authors: Elias, R., Karantanos, T., Sira, E., & Hartshorn, K. L.
Affiliations: Boston University (US)
New York Medical College (US)
Corresponding author: Elias, Rawad
ORCID: Elias, Rawad
Karantanos, Theodoros
Hartshorn, Kevan L.
Venue: Journal of Geriatric Oncology
Publisher: Elsevier BV
Published: 2017-05
Volume: 8
Issue: 3
Pages: 229-235
ISSN: 1879-4068 (ISSN-L)
DOI: 10.1016/j.jgo.2017.02.001
OpenAlex: W2588635414
Cited by: 133
References: 126
Citations by year: 2026: 3 · 2025: 12 · 2024: 13 · 2023: 11 · 2022: 20 · 2021: 18 · 2020: 18 · 2019: 17 · 2018: 16 · 2017: 5
FWCI: 1.60
Type: journal article
Language: en
Open access: closed
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations: Journal of Geriatric Oncology (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
Keywords: immune checkpoint inhibitors, immunosenescence, older adults, cancer immunotherapy, mechanism of action
MeSH terms: Age Factors, Aged, Aging, Antibodies, Monoclonal, Humans, Immunologic Factors, Immunotherapy, Neoplasms

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Immunotherapy comes of age: Immune aging & checkpoint inhibitors

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks